The Cochrane Collaboration, as described on its own website, is, “…an international, independent, not-for-profit organization of over 28,000 contributors from more than 100 countries, dedicated to making up-to-date, accurate information about the effects of health care readily available worldwide.”
“We are world leaders in evidence-based health care,” the site goes on to say, followed by a quote from The Lancet which states, “The Cochrane Collaboration is an enterprise that rivals the Human Genome Project in its potential implications for modern medicine.”
Working for the Cochrane Collaboration, an epidemiologist named Dr. Tom Jefferson decided to take a close look at the scientific evidence behind influenza vaccines (seasonal flu vaccines).
The objectives of the study were to: “Identify, retrieve and assess all studies evaluating the effects of vaccines against influenza in healthy adults.”
The corresponding figures [of people showing influenza symptoms] for poor vaccine matching were 2% and 1% (RD 1, 95% CI 0% to 3%)” say the study authors. And by “poor vaccine matching,” they mean that the strain of influenza viruses in the vaccine are a poor match for the strains circulating in the wild. This is usually the case in the real world because the vaccine only incorporates last year’s viral strains and cannot predict which strains will be circulating this year.
In other words, you would have to vaccinate 100 people to reduce the number of people showing influenza symptoms by just one. For ninety-nine percent of the people vaccinated, the vaccine makes no difference at all!
In a “best case” scenario when the viral strain in the influenza vaccine just happens to match the strain circulating in the wild — a situation that even the study authors call “uncommon” — the results were as follows: “4% of unvaccinated people versus 1% of vaccinated people developed influenza symptoms (risk difference (RD) 3%, 95% confidence interval (CI) 2% to 5%).”
In other words, the matching vaccine (which is uncommon in the real world) reduced influenza infections in 3 out of 100 people. Or, put another way, 97% of those injected with the vaccine received no benefit (and no different outcome).
Furthermore, the study’s conclusions go on to state:
• “Vaccination had… no effect on hospital admissions or complication rates.”
• “Vaccine use did not affect the number of people hospitalized or working days lost.”
• “The review showed that reliable evidence on influenza vaccines is thin but there is evidence of widespread manipulation of conclusions…”
• “There is no evidence that [influenza vaccines] affect complications, such as pneumonia, or transmission.” (Got that? Vaccines do not affect transmission of the disease, yet that’s the whole reason vaccines are pushed so heavily during pandemics — to block disease transmission.)
• “In average conditions (partially matching vaccine) 100 people need to be vaccinated to avoid one set of influenza symptoms.”
And finally, the study author’s summary concludes with this whopper of a statement: “Our results may be an optimistic estimate because company-sponsored influenza vaccines trials tend to produce results favorable to their products and some of the evidence comes from trials carried out in ideal viral circulation and matching conditions and because the harms evidence base is limited.”